Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 23-27

  Van Allen, E M ^a,b   Foye, A ^c   Wagle, N ^a,b   Kim, W ^c   Carter, S L ^b   McKenna, A ^b,d   Simko, J P ^c   Garraway, L A ^a,b   Febbo, P G ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

bone biopsy; genomics; precision medicine; whole exome sequencing

Indexed keywords

BIOPSY; BONE TUMOR; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; EXOME; GENETICS; GERMLINE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROSTATE TUMOR; RADIOGRAPHY; SECONDARY;

BIOPSY; BONE NEOPLASMS; EXOME; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84894088378     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.37     Document Type: Article

References (26)

1. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Translational Med 2011;3:111ra21.
2. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P et al. Highthroughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discovery 2012;2:82-93.
3. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
4. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
5. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-243.
6. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011;17:3924-3932.
7. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006;12:152-158.
8. Fisher S, Barry A, Abreu J, Minie B, Nolan J, Delorey TM et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol 2011;12:R1.
9. Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res 2013;23:228-235.
10. Van Allen E, Wagle N, Kryukov G, Ramos A, Getz G, Garraway L. A heuristic platform for clinical interpretation of cancer genome sequencing data. J Clin Oncol 2012, (suppl; abstr 10502).
11. Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW et al. Somatic mutations of PIK3R1 promote gliomagenesis. PloS One 2012;7:e49466.
12. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
13. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-689.
14. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP). Seattle, WA, USA 2012.
15. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008;68:3523-3531.
16. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 2011;306(14):1557-1565.
17. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
18. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int 2012;110:1729-1735.
19. Van Allen EM, Pomerantz M. Moving toward personalized medicine in castrationresistant prostate cancer. Urol Clinics North Am 2012;39:483-490.
20. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-586.
21. Spritzer CE, Alfonso PD, Vinson EN, Turnbull JD, Morris KK, Foye A et al. Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer - factors affecting diagnostic success. Radiology 2013;269:816-823.
22. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA et al. Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusionpositive prostate cancer. Cancer Cell 2011;19:664-678.
23. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al. Therapeutic targeting of SPINK1-positive prostate cancer. Sci Translational Med 2011;3:72ra17.
24. Cibulskis K, McKenna A, Fennell T, Banks E, DePristo M, Getz G. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 2011;2718:2601-2602.
25. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-1303.
26. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-219.